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Abstract: In order to examine the efﬁ  cacy and side effects of the monoclonal antibody anti-CD20 
(rituximab) on autoimmune blistering skin diseases, we performed a comprehensive survey of 
71 consecutive patients from initial use up to 2007, using the PubMed database. A heterogeneous 
group of patients, including 51 patients with pemphigus vulgaris, one with pemphigus vegetans, 
nine with pemphigus foliaceus, ﬁ  ve with paraneoplastic pemphigus, four with epidermolysis 
bullosa acquisita, and one with both bullous pemphigoid and graft vs host disease was included 
in this survey. Overall the monoclonal antibody seems to be effective in that 69% of patients 
showed complete response, 25% of patients showed partial response, whereas 6% of patients 
showed progressive disease. Six deaths occurred in association with the treatment, with four 
of these deaths in patients with paraneoplastic pemphigus, a disease characteristically resistant 
to conventional medication and with a high mortality rate. Of note, 11 patients who received 
combined rituximab and intravenous immune globulin treatments had the best outcome: complete 
response without any serious side effects. Therefore further investigation on rituximab with 
controlled clinical trial is a worthy pursuit.
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Introduction
The anti-CD20 antibody, rituximab, which targets B cells, has been recently been 
used experimentally in patients affected by autoimmune blistering skin diseases, such 
as pemphigus and bullous pemphigoid. In the majority of reported cases, patients 
responded well; however, in a few cases, serious infections have resulted from the 
treatment. This article attempts to analyze the effectiveness, the potential side effects, 
and the precautionary measures the physicians should perform to minimize the serious 
infections or other side effects.
Methods
We performed a PubMed literature search utilizing rituximab including the following 
phrases in various combinations; pemphigus, pemphigoid, epidermolysis bullosa acquisita, 
bullous, and blistering. All case reports and studies were included in which rituximab was 
used to treat an autoimmune blistering disease. Articles excluded were those not written in 
English or providing a detailed abstract in English. Our literature search was performed at 
the end of August 2007, and therefore includes all articles present on PubMed at this time. 
We deﬁ  ned complete response to indicate resolution of all mucocutaneous lesions. Partial 
response was deﬁ  ned as greater than 50% improvement of all mucocutaneous lesions. 
Progressive disease was deﬁ  ned as patients that showed less than 50% improvement Therapeutics and Clinical Risk Management 2009:5 2
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of mucocutaneous lesions. We classiﬁ  ed short-term adverse 
events as an event that occurred from the start of the treatment to 
the end of the treatment. Mid-term adverse events were identi-
ﬁ  ed as occurring up to six months post-treatment. Long-term 
adverse events are those adverse events that transpired from 
six months up to ﬁ  ve years post-treatment.
Results
Of the 71 patients included in this review, 51 had pemphigus 
vulgaris, one had pemphigus vegetans, nine had pemphigus 
foliaceus, ﬁ  ve had paraneoplastic pemphigus, four with 
epidermolysis bullosa acquisita, and one patient with simul-
taneous bullous pemphigoid and graft versus host disease. 
In regards to clinical response to rituximab, 49 (69.01%) 
showed a complete response, 18 (25.35%) showed partial 
response, and four (5.63%) showed progressive disease 
(Table 1). Overall, 67 (94.37%) of patients included in this 
review showed complete or partial clinical improvement. Of 
note, in the four patients with progressive disease, one had 
pemphigus foliaceus, one had pemphigus vegetans, and the 
other two had paraneoplastic pemphigus. The latter of these 
is characteristically resistant to all conventional treatments if 
the associated primary tumors can not be entirely removed.
There were six deaths total in association with rituximab 
usage: two short term, two mid term, and two long term. Of 
the deaths four had paraneoplastic pemphigus, one pemphigus 
vulgaris, and one bullous pemphigoid and graft versus host dis-
ease. Most causes of death were attributed to sepsis, congestive 
heart failure, or pneumonia. All cases of death involved patients 
treated with rituximab without combining intravenous immune 
globulin (IVIg). Complications from infection included four 
cases of sepsis or bacteremia (three short term and one long 
term), two cases of pneumonia (short term: pneumocystis 
pneumonia which led to death; mid term: community acquired 
pneumonia), and one case of infective arthritits (mid term due 
to Pseudomonas aeruginosa). A patient with paraneoplastic 
pemphigus developed ocular herpes simple virus (long term), 
varicella (long term), and Mycobacterium chelonae cutaneous 
infection (long term). Other short-term complications included 
atrial ﬁ  brillation with congestive heart failure which led to 
death in a patient with paraneoplastic pemphigus and deep 
venous thrombosis in a patient with epidermolysis bullosa 
acquisita. Of important note all complications, including death, 
were limited to 10 of the 71 patients.
Discussion
Rituximab is an anti-CD20 chimeric monoclonal antibody 
that targets pre-B cells, immature B cells, naïve B cells, 
and memory B cells.1 Plasma and stem cells lack CD20 and 
therefore are not targeted by rituximab.1,2 After binding of 
rituximab to CD 20+ cells, cells undergo apoptosis via direct 
effect, complement and antibody dependent cytotoxicity, and 
inhibition of cell proliferation.2–4 Recovery of B cells begins 
6–9 months after rituximab treatment, with levels returning to 
normal one year later.5 Kazkaz and colleagues, Sundharam, 
and Cooper and colleagues reported no autoantibody titers 
reduction during the treatment with rituximab,2,3,6 while 
Neidermeier and colleagues, Goebler and colleagues, and 
Herrmann and colleagues did report a decrease in antibody 
titers to desmoglein 3 and/or desmoglein 1.7–9 As noted by 
Antonucci, in the cases of complete response to rituximab, 
clinical improvement is not always associated with a decrease 
in autoantibody titers, which might be secondary to the 
different life spans of antibody producing plasma cells.10 In 
the small study by Arin and colleagues, some but not all patients 
experienced a decrease in antibody titers to desmoglein 1 and 
3 associated with improvement in their disease.5 In a child with 
pemphigus foliaceus, the clinical improvement by rituximab 
treatment was associated with reduction of anti-desmoglein 
1 autoantibodies (from 1:1,280 to 1:16 after 7 courses of 
treatment).11 Interestingly, Marzano and colleagues reported 
that only those patients affected by pemphigus foliaceus, and 
not those affected by pemphigus vulgaris, showed reduction 
of anti-desmoglein autoantibody titer in parallel with clinical 
improvement.12 Niedermeier and colleagues also reported a 
patient with epidermolysis bullosa acquisita with complete 
remission after rituximab treatment, had clinical improve-
ment which paralleled the decline of anti-basement membrane 
autoantibody titer.13 Furthermore, Ahmed and colleagues and 
Schmidt and colleagues reported reduction of autoantibody 
titers during the treatment with combined rituximab and 
IVIg.14,15 To what extent does the IVIg contribute to the autoan-
tibody titer reduction is not clear and cannot be determined by 
the published data derived from this combined rituximab/IVIg 
study.14 In the previous studies of IVIg treatment for patients 
with pemphigus, it was reported that the autoantibody titers 
did reduce during the treatment.16
Rituximab was originally developed to treat refractory, 
low-grade, follicular, B cell non-Hodgkins lymphoma2, 
but has been used experimentally in various autoimmune 
diseases including autoimmune blistering disorders (pemphi-
gus vulgaris,5–7,9–10,12,14,17–27 pemphigus vegetans,12 pemphigus 
foliaceus,5,8,11,12,28 paraneoplastic pemphigus,29–33 bullous 
pemphigoid,34 and epidermolysis bullosa acquisita13,35,36), 
systemic lupus erythematosus, Sjögren’s syndrome, dermato-
myositis, rheumatoid arthritis, myasthenia gravis, Wegner’s Therapeutics and Clinical Risk Management 2009:5 3
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Table 1 Survey data from 71 consecutive patients from the initial use of anti-CD20 therapy for autoantibody-mediated blistering skin 
diseases until 2007
Diagnosis Cycles
of rituximab
Concomitant 
meds
Response Short 
term ae
Mid
term ae
Long
term ae
Ref
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PF
PF
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PV
PF
PF
PF
PF
1
1
1
1
1
1
1
1
1
1
1
1
2, then mo
2, then mo
2, then mo
2, then mo
2, then mo
2, then mo
2, then mo
2, then mo
2, then mo
3, then mo
4, then mo
1, then q 2 wk
1
1
1
1, then q mo
2
2
1
1
1
1
1
1
1, then q 4–8 wk
1
1
1
1
1
2 (1 q year)
1
1
1
1
1
1
1
1
1
1
1
q wk × 12, then q 2 wk 
IVIG, NOS
IVIG, NOS
IVIG, NOS
IVIG, NOS
IVIG, NOS
IVIG, NOS
IVIG, NOS
IVIG, NOS
IVIG, NOS
IVIG, NOS
IVIG, NOS
STpo, IVIG, MMF, CYP 
STpo
STpo, CYP
STpo, MMF
STpo, STiv, MMF
STpo, AZA
STpo, CYA, AZA
STpo
STpo
STpo, MMF
STpo
STpo
STpo, IVIG, MMF
STpo,
STpo, CYP
STpo, CYP
CYP
STpo
STpo
STpo
STpo
STpo
STpo, AZA
STpo, AZA
STpo, MTX
STpo, MTX
STpo, AZA
STpo, CYP, IVIG
STiv
STpo
CR
CR
CR
CR
PR
CR
CR
CR
CR
PR
CR
PR
CR
CR
CR
CR
CR
CR
CR
CR
CR
CR
CR
PR
PR
CR
PR
CR
PR
PR
CR
CR
CR
PR
CR
CR
CR
CR
CR
PR
CR
CR
CR
CR
CR
CR
CR
CR
PR
PR
CR
CR
PD
CR
CR
Pneumonia, Death 
Pneumonia 
Infective 
arthritis 
17
14
18
9
19
6
20
21
22
7
23
24
15
25
26
27
10
5
28
8
11
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granulomatosis,1 idiopathic thrombocytopenic purpura, 
type II mixed cryoglobulinemia,37 autoimmune hemolytic 
anemia, IgM-associated polyneuropathies, pure red cell 
aplasia, and thrombotic thrombocytopenia purpura.4
Autoimmune blistering disorders are characterized by 
vesiculobullous eruptions affecting the skin and/or mucous 
membranes secondary to antibodies against cell surface 
antigens1 pemphigus or basement membrane antigens 
(bullous pemphigoid34 and epidermolysis bullosa acquisita35). 
Although autoreactive T cells have been identiﬁ  ed in some 
of these patients, the effector cells are autoreactive B cells 
by way of their tissue-speciﬁ  c autoantibodies. The pemphi-
gus group has intraepidermal (ﬂ  accid) bullae and includes 
pemphigus vulgaris, pemphigus foliaceus, and paraneo-
plastic pemphigus. Pemphigus vulgaris is due to antibodies 
against desmoglein 3 (in the mucosal variant) or desmoglein 
1 and 3 (in the mucocutaneous variant). Pemphigus foliaceus 
is a more superﬁ  cial form of pemphigus with antibodies 
directed against only desmoglein 1.1 Finally, paraneoplastic 
pemphigus is a variant of pemphigus associated with 
non-Hodkins lymphoma, chronic lymphocytic leukemia, 
thymoma, or Castleman’s disease and has a variety of 
target epithelial antigens.29,31 Paraneoplastic pemphigus 
carries a poor prognosis, with a 2 year 90% mortality rate.29 
Bullous pemphigoid is characterized by tense, subepider-
mal, blisters of the skin due to antibodies against basement 
membrane antigens, bullous pemphigoid antigens 1 and 2.34 
Epidermolysis bullosa acquisita is another subepidermal 
blistering disorder with antibodies against collagen VII, a 
component of the basement membrane zone, and is often 
recalcitrant to conventional treatment.35
The autoimmune blistering disorders mentioned above 
are all conventionally treated with topical corticosteroids 
along with systemic corticosteroids and/or other systemic 
immunosuppressants. Most patients respond favorably to 
conventional regimens; however, a minority of patients fails 
and other treatment options must be considered. Even for 
those patients who respond to the conventional treatment reg-
imens of systemic corticosteroid and immunosuppressives, 
the side effects these patients encountered could be very 
substantial.38 Many patients developed steroid-induced 
diabetes, osteoporosis, pathologic fracture of bones, and 
serious infections.39,40 For these reasons, treatment options 
alternative to systemic corticosteroid and immunosuppres-
sives are always sought by clinicians who care for this group 
of patients. The ﬁ  rst reported use of rituximab was in a 
patient with follicular lymphoma-associated paraneoplastic 
pemphigus.32 Thereafter, reports emerged of rituximab used 
in the treatment of pemphigus vulgaris,5–7,9,10,12,14,17–27 pemphi-
gus vegetans,12 pemphigus foliaceus,5,8,11,12,28 paraneoplastic 
pemphigus,29–33 bullous pemphigoid,34 and epidermolysis 
bullosa acquisita.13,35,36
Table 1 (Continued)
Diagnosis Cycles
of rituximab
Concomitant 
meds
Response Short 
term ae
Mid
term ae
Long
term ae
Ref
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
PNP
PNP
PNP
PNP
PNP
BP + GVHD
EBA
EBA
EBA
EBA
PVg
PV
PV
PF
PF
PF
1
1/2
1, then q 2 wk
1, then q 2 mos
3
1
1
1
1
1
1, then q mo
1, 10 mos later q wk × 2
1
1
1
1
STpo
STpo, CYP
STpo
STpo, CYP, DOX, VIN
STpo, CYP, VIN
Anti-CD-25, STpo, MMF
STpo, AZA, COL
STpo, MMF
STpo, IA, MMF
STpo, IA, MMF
STpo
STpo
STpo, CYP
STpo
STpo
PR
PD
PR
PR
PD
CR
CR
PR
CR
PR
PD
CR
PR
CR
CR
CR
Bacteremia
Death, Sepsis 
AFIB, CHF, Death
DVT
Death
Sepsis, HSV, VZV, M. 
chenolae, Death
Death, Sepsis
29
30
31
32
33
34
35
36
13
12
Abbreviations: Anti-CD-25, anti-CD-25 antibody; AZA, azathioprine; COL, colchicines; CYA, cyclosporine A; CYP, cyclophosphamide; DAP, dapsone; DOX, doxorubicin; IVIG, 
intravenous immunoglobulin; IA, immunoabsorption; MMF, mycophenolate mofetil; MTX, methotrexate; NOS, Immunosuppressant not otherwise speciﬁ  ed; PHO, extracorporeal 
photopheresis; PLA, plasmaphoresis; Stpo, steroids po; STiv, steroids intravenous; TS, trimethoprim/sulfamethazole; VIN, vincrsitine; CR, complete response; PR, partial response; 
PD, progressive disease; BP, bullous pemphigoid; EBA, epidermolysis bullosa acquisita; GVHD, graft versus host disease; PF, pemphigus foliaceus; PNP, paraneoplastic pemphigus; 
PV, pemphigus vulgaris; PVg, pemphigus vegetans; Ref, reference; ae, adverse effect associated with use of rituximab.Therapeutics and Clinical Risk Management 2009:5 5
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Most commonly, rituximab is administered as a cycle of 
weekly infusions of 375 mg/m2 for four weeks.1 However, 
other infusion regimens have been described, includ-
ing repeating a full cycle and/or monthly or every other 
week “X”.14,25,31 Concominant systemic therapy used 
during rituximab treatment have included prednisone, 
dexamethasone, mycophenolate mofetil, azathioprine, 
cyclophosphamide, colchicine, methotrexate,41 IVIg, plas-
maphoresis,42 daclizumab (anti-CD25 antibody),34 and 
immunoabsorption.13
As noted earlier, in this review we found 69.01% of 
autoimmune blistering patients treated with rituximab 
showed a complete response and 25.35% showed partial 
response. Collectively, 67 (94.37%) of patients showed 
clinical improvement. Of the patients with progressive 
disease despite rituximab therapy, one had pemphigus 
foliaceus, one had pemphigus vegetans, and the other two 
had paraneoplastic pemphigus. Although the exact duration 
of response of all reported patients treated with rituximab can 
not be accurately determined as many of these case reports 
contain a short follow-up time, we can safely state that current 
literatures indicate that the duration of response can last from 
at least 3 months23,32 to as long as 37 months.14 Furthermore, 
it is worthy to point out that the data from Ahmed studies 
suggest that combined IVIg and rituximab have the most 
promising effectiveness, resulting in complete response in 
all 11 treated patients (Table 1).
Most side effects secondary to rituximab occur 
at the time of infusion, are mild and transient, and 
include: headache,41 fever, chills, nausea, shortness of 
breath, postural hypotension,1 pruritus, uticaria,37 and 
bronchospasm.18 These adverse events can be prevented 
and/or minimized with premedication of acetaminophen 
and diphenhydramine.1,18,41 Other side effects that have been 
encountered during rituximab usage for various diseases 
are as follows: Stevens-Johnson syndrome, toxic epidermal 
necrolysis, lichenoid dermatitis, vesiculobullous disease, 
vasculitis, acute respiratory distress syndrome, mycocardial 
infarctions, arrythmias, congestive heart failure, pneumoni-
titis, tumor lysis syndrome, sepsis, hepatitis B reactivation 
with fulminant hepatitis, acute renal failure, anemia, lym-
phopenia, leukopenia, neutropenia, thrombocytopenia,37 
meningoencephalitis,42 herpes zoster, varicella virus, Epstein 
Barr virus, and cytomegalovirus reactivation, pneumonia,43 
and serum sickness.44 Additionally, progressive multifocal 
leukoencephalopathy has been reported in patients with sys-
temic lupus erythematosus patients receiving treatment with 
rituximab.45 The most severe adverse event encountered in 
our review was death. A total of six deaths were associated 
with rituximab in these 71 patients. The distribution of the 
deaths as related to time was as follows; two short term, two 
mid term, and two long term. Of the patients that expired, 
four had paraneoplastic pemphigus, one pemphigus vulgaris, 
and one bullous pemphigoid and graft versus host disease. 
Most causes of death were attributed to sepsis, congestive 
heart failure, or pneumonia. It is also noteworthy that while 
these six bullous disease patients died while being treated 
with rituximab, these patients also had many confounding 
factors including underlying disease mortality, other pre-
existing diagnosis, and polypharmacy. Again, IVIg was not 
included in these six patients’ therapeutic regimens.
While many authors reported that rituximab carries no 
increased risk of infection,17,18,22 the rituximab package insert 
does warn of an increase risk of infection and seven of the 
71 patients included in this review had infections (Table 1). 
While a few bullous disease patients have developed serious 
infections on rituximab, these patients also had many con-
founding factors such as concomitant and past usage of 
immunosuppressants, underlying disease mortality (espe-
cially pemphigus vulgaris and paraneoplastic pemphigus), 
and other pre-existing diagnosis (for example, cancer or 
diabetes, which can cause immunosuppression) which have 
made them more susceptible to infections. To decrease 
the risk of infection while on rituximab it has been recom-
mended to screen for hepatitis B virus, hepatitis C virus, 
and human immunodeficiency virus prior to treatment. 
Furthermore, close monitoring for signs of infection and 
prompt prescription of treatment for infection are essential.1,43 
Rituximab should be avoided or used with extreme caution 
in autoimmune blistering disease patients with liver, kidney, 
neurological, or psychological disease, severe osteoporosis, 
immunodeﬁ  ciency, active infections, history of cancer other 
than a lymphoproliferative disorder for which the patient 
might be receiving rituximab treatment with, and pregnant 
or lactating women, and used with cautiously in those with 
a history of cardiac disease such as angina and arrhythmias.1 
Furthermore, long term consequences of rituximab are 
unknown and clinical trials are lacking.17
Although it can not be concluded from this small review, it 
is worthy noting that combined IVIg and rituximab treatment 
seems to have the least possibility of having serious infection 
(Table 1). In fact, none of the death has resulted in patients 
treated with combined rituximab and IVIg. A possible expla-
nation is that the complete blockade of antibody production 
by anti-CD20 (rituximab) as a single treatment regimen to 
these patients may eliminate their abilities to defend against Therapeutics and Clinical Risk Management 2009:5 6
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pathogens that are vulnerable to humoral immunity, therefore 
opening door for serious infections. However, the concomitant 
IVIg treatment could at least partially compensate for these 
patients’ loss of humoral immunity by providing an exter-
nally produced antibody mixture, among them are antibodies 
speciﬁ  c for a variety of pathogens. Further, well-controlled 
studies are needed to determine if combination treatment of 
rituximab and IVIg leads to a decreased rate of infection, in 
comparison with treatment with rituximab alone.
Conclusion
In the analyses of these 71 patients treated with ritux-
imab or combination of rituximab and IVIg, we found 
that 67 (94.37%) of treated patients showed complete or 
partial clinical improvement. A total of six deaths were 
seen in the 71 patients; however, all patients had either a 
disease with an extremely poor prognosis (paraneoplastic 
pemphigus and graft versus host disease) or were exception-
ally ill prior to rituximab administration (the pemphigus 
vulgaris patient). Infectious complications in autoimmune 
blistering patients treated with rituximab included sepsis, 
bacteremia, pneumonia, infective arthritis, herpes zoster, 
herpes simplex, and cutaneous Mycobacterium infection. 
Other noted side affects in our review included atrial ﬁ  bril-
lation, congestive heart failure, and deep venous thrombosis. 
As mentioned early, these complications were limited to 10 of 
the 71 patients, and rituximab was well tolerated in the vast 
majority of patients. While, rituximab is a valuable treatment 
in autoimmune bullous diseases recalcitrant to other thera-
pies, the risks of rituximab therapy must be weighed against 
the beneﬁ  ts on a case by case basis. Finally, the high rate of 
complete responses and the absence of serious side effects 
in a report of 11 patients treated with combined rituximab 
and IVIg should serve as an encouraging stimulus for 
a well-controlled clinical trial. However, the extremely high 
cost of combined rituximab and IVIg therapy may prove to be 
a road block for it to become a standard treatment option.
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